Veloxis Pharmaceuticals announces financial results for the first six months of 2015 and improves the full year outlook

Aug 26, 2015, 13:21 ET from Veloxis Pharmaceuticals

HORSHOLM, Denmark, Aug. 26, 2015 /PRNewswire/ --

Highlights:

  • On 14 August, 2015 Envarsus® XR was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus.
  • On 10 July, 2015 Veloxis has received U.S. Food and Drug Administration (FDA) approval of Envarsus® XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus® XR. Veloxis expects Envarsus® XR to be available to patients in the United States and their physicians by the end of 2015.
  • On 12 June, 2015 the U.S. District Court for the District of Columbia ruled in favor of the U.S. Food and Drug Administration (FDA) in the lawsuit filed by Veloxis against FDA. The Court's ruling left intact FDA's 30 October, 2014 tentative approval of Envarsus® XR (tacrolimus extended-release tablets), which delayed full approval for use in newly transplanted kidney transplant recipients ("de novo" patients). Veloxis submitted revised labeling to FDA on 12 June, 2015 with the goal of making Envarsus® XR available for kidney transplant patients who wish to convert from twice-daily tacrolimus products to once-daily Envarsus® XR.
  • Top-line results of the ASTCOFF study was announced, A STeady-state Pharmacokinetic COmparison Of all FK-506 Formulations, which demonstrated that once-daily Envarsus® XR (tacrolimus extended-release tablets) exhibits a differentiated pharmacokinetic (PK) profile when compared to twice-daily tacrolimus (Prograf®) or the once-daily tacrolimus product (Astagraf XL®).
  • Clinical study data was announced which demonstrated that a lower dose of once-daily Envarsus® XR in African-American kidney transplant patients is sufficient to achieve therapeutic tacrolimus blood concentrations, compared to the daily dose required for twice-daily immediate release tacrolimus, and also results in a lower peak concentration and intra-day fluctuation.
  • Veloxis reported a net loss of DKK 66.1 million for the first half of 2015 compared to a net loss of DKK 53.1 million for the same period in 2014. The reported net loss is in line with expectations.
  • For the first half of 2015, Veloxis' sales and marketing costs amounted to DKK 19.5 million compared to DKK 13.7 million during the same period in 2014. Research and development costs amounted to DKK 39.1 million compared to DKK 51.0 million during the same period in 2014.
  • On 30 June, 2015, Veloxis had cash and cash equivalents of DKK 191.1 million.
  • The full year outlook for 2015 is improved. Veloxis now expects an operating loss in the range of DKK 175 - 205 million, and a net loss in the range of DKK 155 - 185 million. Veloxis' cash position is expected to be in the range of DKK 100 - 130 million at year-end 2015.

Outlook for 2015
The full year outlook for 2015 is improved. Veloxis now expects a net loss in the range of DKK 155 - 185 million. This compares with expectations of DKK 195 - 235 million announced in connection with the annual report for 2014.

The improvement is driven by the granted Orphan Drug status which entitles Veloxis to a waiver of the FDA prescription drug user fees for Envarsus® XR, along with overall cost savings.

Cash and cash equivalents are expected to be in the range of DKK 100 – 130 million at 31 December 2015. This compares with previous expectations of DKK 55 – 95 million.

Conference call
A conference call will be held tomorrow, 27 August, 2015 at 3:00 PM CET (Denmark); 2:00 PM GMT (London), 9:00 AM EST (New York).

To access the live conference call, please dial one of the following numbers:
+45 38 48 75 13 (Denmark)
+44 (0) 20 3427 1909 (UK)
+1 646 254 3360 (USA)
Access code 9488658

Following the conference call, a recording will be available on the company's website http://www.veloxis.com.  

Business update
Envarsus® study program
Veloxis is conducting a series of Phase IIIb/IV studies to further evaluate potential differences in clinical profile provided by Envarsus®' unique PK profile. The first study completed was the STRATO (Switching kidney TRAnsplant patients with Tremor to LCP-tacrO) study of Envarsus® in kidney transplant recipients experiencing drug-induced tremors which demonstrated significant overall improvements following the switch to Envarsus®.

Additionally, the ASERTAA (A Study of Extended Release Tacrolimus in African-Americans) Phase IIIb study of Envarsus® in kidney transplant recipients is ongoing. The ASERTAA primary pharmacokinetic results were presented at the American Transplant Congress in Philadelphia on 3 May, 2015. Final data from this study will be presented at the European Society of Organ Transplantation meeting in September, 2015. The key primary outcomes from this study were:

  • The overall PK differences (increased absorption [p<0.0001], lower peak blood concentrations [p<0.0001], less peak-to-tough fluctuation in blood levels [p<0.0001]) between Envarsus XR and IR-Tac capsules seen previously in studies of kidney transplant recipients were also confirmed in this exclusively African-American patient population.
  • The optimal conversion ratio for once-daily extended release Envarsus XR was shown to be approximately 20% lower than the total IR-Tac daily dose prior to conversion.
  • Peak tacrolimus concentration (Cmax) was reduced 30% for patients on Envarsus while intra-day fluctuation was reduced 50%.
  • Envarsus XR's PK parameters were less impacted by CYP3A5 genotype. IR-Tac was more affected by the presence of the *1 allele, driven primarily by the need to increase dose to achieve therapeutic trough levels, which also resulted in an incremental increase in tacrolimus intra-day peak levels.
  • Conversion of African-American patients from IR-Tac to Envarsus XR was demonstrated to be readily achieved with a reduction in dose of approximately 20% without concern for genotype status.

In addition, the ASTCOFF (A STeady-state Pharmacokinetic Comparison Of all FK-506 Formulations) Phase IIIb study is ongoing and primary results were announced in June, 2015. This study examines the pharmacokinetic differences between Envarsus and the other two tacrolimus formulations commercially available, namely Astagraf XL and Prograf. Primary results from this study confirmed previously published data for Envarsus and showed greater bioavailability (p<0.0001) and a flatter PK profile characterized by lower peak-to-trough fluctuation (p<0.001) and delayed time to peak concentrations of 6 hrs (p=<0.001) compared to both Prograf and Astagraf. At equivalent exposure, Envarsus achieves at least a 30% dose reduction requirement and a substantively lower peak blood concentration (p=<0.005) compared to the two comparator products. Final data from this study will be presented at the European Society of Organ Transplantation meeting in September, 2015.

Veloxis conducted two Phase III studies of Envarsus® in kidney transplant recipients as the basis for its development programme for Envarsus® as a once-daily agent for the prophylaxis of organ rejection in kidney transplantation, Study 3001 in maintenance conversion kidney transplant patients and Study 3002 in de novo kidney transplant recipients.

Envarsus® Regulatory Strategy
On 29 April, 2013 a Marketing Authorization Application (MAA) was submitted by Veloxis to the European Medicines Agency (EMA) seeking approval to market Envarsus® for the prevention of organ rejection in transplant patients in the European Union. The MAA submission was based on the favourable results of the Envarsus® Phase III 3001 Study in stable kidney transplant patients and data from an extensive Phase I and II clinical programme and has been accepted for review by the EMA. On 28 July, 2014, it was announced that the European Commission granted marketing authorization for Envarsus® for the prevention of organ rejection in adult kidney and liver transplant patients in the European Union (EU).  Veloxis' marketing and distribution partner Chiesi Farmaceutici launched Envarsus in the EU in late 2014, with launches in Germany and the Netherlands, followed by launch in the UK, Denmark, Austria and Eire in 2015. Additional launches are anticipated for the majority of the major EU countries during 2015, once local requirements such as pricing negotiations have been completed.

Veloxis submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus® XR in the US for the prevention of organ rejection in kidney transplant recipients on 30 December, 2013. On 30 October, 2014 the FDA granted Tentative Approval for Envarsus® XR for the prophylaxis of rejection in kidney transplant patients. FDA stated that the final approval of Envarsus® XR would be delayed until expiration of the exclusivity period for Astellas' Astagraf XL®, for the treatment of newly transplanted ('de novo') patients.. Veloxis disagrees that exclusivity for Astagraf XL®, which was not identified as a listed drug or relied upon to support approval of Envarsus® XR, should require delay in the formal approval of Envarsus® XR.  On 16 December, 2014, Veloxis announced that it had filed an action against the FDA, seeking an order requiring FDA to grant final approval to Envarsus® XR. On 12 June, 2015, Veloxis announced that the U.S. District Court for the District of Columbia had ruled in favor of the FDA in the lawsuit filed by Veloxis against the FDA.  The Court's ruling left intact FDA's 30 October, 2014 tentative approval of Envarsus® XR (tacrolimus extended-release tablets), which delayed full approval for use in newly transplanted kidney transplant recipients ("de novo" patients).  Veloxis submitted revised labeling to FDA with the goal of making Envarsus® XR available for kidney transplant patients who wish to convert from twice-daily tacrolimus products to once-daily Envarsus® XR.

On 10 July, 2015, Veloxis received U.S. FDA approval of Envarsus® XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus® XR.

The build and hiring of the full commercial infrastructure, including a sales team of approximately 18 individuals to call on the top 180 transplant centres in the US, to support launch of Envarsus XR in the US is ongoing and expected to be in place and operational for product launch. Analyses to support determination of the pricing of Envarsus XR are ongoing.

In addition, Envarsus® XR has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus.

 

Financial Highlights















YTD

YTD

Q2

Q2

Year



2015

2014

2015

2014

2014



DKK'000

DKK'000

DKK'000

DKK'000

DKK'000








Income Statement






Revenue

9,576

24,412

5,292

12,206

123,395

Production costs

(5,798)

-

(1,657)

-

(3,247)

Gross profit

3,778

24,412

3,635

12,206

120,148

Sales and marketing costs

(19,457)

(13,653)

(9,637)

(13,653)

(41,278)

Research and development costs

(39,127)

(51,044)

(18,363)

(24,420)

(90,111)

Administrative expenses

(27,573)

(17,732)

(11,549)

(9,983)

(47,363)

Operating result

(82,379)

(58,017)

(35,914)

(35,850)

(58,604)

Net financial income / (expenses)

13,327

1,905

(4,673)

1,228

20,903

Result before tax

(69,052)

(56,112)

(40,587)

(34,622)

(37,701)

Tax for the period

2,958

2,989

1,478

1,495

1,382

Net result for the period

(66,094)

(53,123)

(39,109)

(33,127)

(36,319)








Balance Sheet






Cash and cash equivalents

191,064

264,240

191,064

264,240

270,434

Total assets

224,177

276,493

224,177

276,493

293,723

Share capital

166,334

166,252

166,334

166,252

166,300

Total equity

193,526

231,649

193,526

231,649

253,248

Investment in property, plant and equipment

272

117

272

(169)

1,805








Cash Flow Statement






Cash flow from operating activities

(93,698)

(67,126)

(37,205)

(33,577)

(77,243)

Cash flow from investing activities

(272)

(117)

(272)

169

(2,547)

Cash flow from financing activities

120

684

88

-

989

Cash and cash equivalents at period end

191,064

264,240

191,064

264,240

270,434








Financial Ratios






Basic and diluted EPS

(0.04)

(0.03)

(0.02)

(0.02)

(0.02)

Weighted average number of shares

1,663,085,535

1,661,684,858

1,663,167,653

1,662,527,283

1,662,266,639

Average number of employees (FTEs)

30

23

31

23

26

Assets/equity

1.16

1.19

1.16

1.19

1.16

Share price

0.86

1.80

0.86

1.80

1.15

 

The interim report has not been audited or reviewed by the company's independent auditors.

Revenue
For the first half of 2015 Veloxis recognized revenue of DKK 9.6 million compared to DKK 24.4 million in the same period of 2014. Revenue in 2015 consist of commercial sales to Chiesi Farmaceutici S.p.A. Revenue in 2014 consist of up-front and milestone payments under Veloxis' distribution agreement with Chiesi Farmaceutici S.p.A. Envarsus is currently launched in Germany, Netherlands, UK, Denmark, Austria and Eire.

Sales and marketing costs
For the first half of 2015, Veloxis' sales and marketing costs amounted to DKK 19.5 million compared to DKK 13.7 million during the same period in 2014. This reflects the building of the marketing and sales infrastructure in the US.

Research and development costs
For the first half of 2015, Veloxis' research and development costs amounted to DKK 39.1 million compared to DKK 51.0 million during the same period in 2014. The reduction in cost is associated with the overall reduction in study activity as studies are being completed.

Administrative expenses
For the first half of 2015, Veloxis' administrative cost amounted to DKK 27.6 million compared to DKK 17.7 million during the same period in 2014. The increase in cost is mainly attributable to legal fees in connection with legal actions against the FDA.

Compensation costs
For the first half of 2015, a total of DKK 6.5 million was recognized as share-based compensation. The cost is included in S&M, R&D and Admin. The comparable cost for 2014 was DKK 5.0 million.

In the second quarter of 2015, a total of 633,334 warrants have been cancelled, a total of 1,009,775 warrants have expired and a total of 250,000 warrants have been exercised at an exercise price of DKK 0.35.

On 30 June, 2015, there were a total of 126,960,900 warrants outstanding at an average strike price of DKK 0.69. Members of the Board of Directors held 5,107,815 warrants at an average strike price of DKK 0.90. Members of the Executive Management held 76,170,781 warrants at an average strike price of DKK 0.59, while other current and former employees held 45,682,304 warrants at an average strike price of DKK 0.84.

Please refer to Veloxis' latest annual report for additional details on the Company's warrant programs.

Operating loss
Veloxis' operating loss for the first half of 2015 was DKK 82.4 million compared to DKK 58.0 million in the corresponding period of 2014.

Financial income
During the first half of 2015, the Company recognized net financial income of DKK 13.3 million compared to net financial income of DKK 1.9 million in the corresponding period of 2014. The income is mainly due to unrealized currency gains following an increase in the USD / DKK currency rate during the first half of 2015.

Net loss
Veloxis' net loss for the first half of 2015 was DKK 66.1 million compared to DKK 53.1 million in the corresponding period of 2014.

Cash flow
On 30 June, 2015, the balance sheet reflects cash and cash equivalents of DKK 191.1 million compared to DKK 270.4 million on 31 December, 2014. This represents a decrease of DKK 79.3 million primarily related to the Company's operating activities for the period.

Balance sheet
On 30 June, 2015, total assets were DKK 224.2 million compared to DKK 293.7 million at the end of 2014.

Shareholders' equity equalled DKK 193.5 million on 30 June, 2015, compared to DKK 253.2 million at the end of 2014.

Significant risks and uncertainties
Veloxis faces a number of risks and uncertainties related to operations, research and development, commercial and financial activities. For further information about risks and uncertainties, we refer to the Annual Report for 2014. As of the date of this Interim Report, there have been no significant changes to Veloxis' overall risk profile since the publication of the Annual Report for 2014.

For more information, please contact:       





William J. Polvino    



Johnny Stilou

President & CEO         



EVP, Chief Financial Officer

Phone: +1 732 321 3202        



Phone: +45 3053 3364

Email: wjp@veloxis.com          



Email: jst@veloxis.com  

The forward looking statements and targets contained herein are based on the current view and assumptions of the Executive Management and the Board of Directors of Veloxis Pharmaceuticals A/S. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Veloxis Pharmaceuticals A/S expressly disclaim any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this interim report to reflect any change in events, conditions, assumptions, or circulations on which any such statements are based unless  required by applicable law.

About Envarsus®
Tacrolimus is a leading immunosuppression drug used for the prevention of transplant allograft rejection after organ transplantation. Envarsus® (tacrolimus prolonged-release tablets) has received marketing authorization in the EU for prophylaxis of organ rejection in kidney and liver transplant recipients. In the U.S., Envarsus®, known as Envarsus® XR (tacrolimus extended-release tablets), is approved for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations. Envarsus® XR has received orphan drug designation in the U.S. Veloxis plans to commercialize Envarsus® XR in the U.S. through its own sales force and in the EU through its partnership with Chiesi Farmaceutici SpA. 

About Veloxis Pharmaceuticals
Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.

Executive Management's and the Board of Directors' Statement on the Interim Report

The Executive Management and the Board of Directors have considered and adopted the Interim Report for the 6 months ended 30 June 2015 of Veloxis Pharmaceuticals A/S.

The Interim Report is prepared in accordance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and additional Danish disclosure requirements for financial reporting of listed companies.

We consider the applied accounting policies to be appropriate and, in our opinion, the Interim Report gives a true and fair view of the assets and liabilities, financial position, results of the operation and cash flow of the group for the period under review. Furthermore, in our opinion the management review includes a fair review of the development and performance of the business and the financial position of the group, together with a description of the material risks and uncertainties the group faces.

Horsholm, 26 August, 2015




Executive Management




Dr. William J. Polvino         

Johnny Stilou                                                   

President & CEO         

Executive Vice President & CFO                    



Board of Directors




Mette Kirstine Agger         

Thomas Dyrberg                                              

(Chairman)                                     

(Deputy Chairman)



Anders Gotzsche                    

Michael Heffernan                                                 

 

 


Financial Highlights








Quarterly Numbers in DKK



















Q2

Q1


Q4

Q3

Q2

Q1



2015

2015


2014

2014

2014

2014



DKK'000

DKK'000


DKK'000

DKK'000

DKK'000

DKK'000










Income Statement








Revenue

5,292

4,284


3,214

95,769

12,206

12,206

Production costs

(1,657)

(4,141)


(3,247)

-

-

-

Gross profit

3,635

143


(33)

95,769

12,206

12,206

Sales and marketing costs

(9,637)

(9,820)


(17,246)

(10,378)

(13,653)

-

Research and development costs

(18,363)

(20,764)


(19,677)

(19,391)

(24,420)

(26,624)

Administrative expenses

(11,549)

(16,024)


(19,375)

(10,256)

(9,983)

(7,749)

Operating result

(35,914)

(46,465)


(56,331)

55,744

(35,850)

(22,167)

Net financial income / (expenses)

(4,673)

18,000


5,666

13,332

1,228

677

Result before tax

(40,587)

(28,465)


(50,665)

69,076

(34,622)

(21,490)

Tax for the period

1,478

1,480


1,488

(3,095)

1,495

1,494

Net result for the period

(39,109)

(26,985)


(49,177)

65,981

(33,127)

(19,996)










Balance Sheet








Cash and cash equivalents

191,064

233,568


270,434

310,571

264,240

296,237

Total assets

224,177

262,656


293,723

330,127

276,493

305,373

Share capital

166,334

166,309


166,300

166,300

166,252

166,252

Total equity

193,526

228,715


253,248

300,456

231,649

261,538

Investment in property, plant and equipment

272

-


1,149

540

(169)

285










Cash Flow Statement








Cash flow from operating activities

(37,205)

(56,494)


(42,139)

32,023

(33,577)

(33,550)

Cash flow from investing activities

(272)

-


(1,891)

(540)

169

(285)

Cash flow from financing activities

88

33


-

304

-

684

Cash and cash equivalents at period end

191,064

233,568


270,434

310,571

264,240

296,237










Financial Ratios








Basic and diluted EPS

(0.02)

(0.02)


(0.03)

0.04

(0.02)

(0.01)

Weighted average number of shares

1,663,167,653

1,663,002,504


1,662,997,314

1,662,680,554

1,662,527,283

1,660,833,074

Average number of employees (FTEs)

31

30


31

28

23

22

Assets/equity

1.16

1.15


1.16

1.10

1.19

1.17

 

 


Income statement and statement of comprehensive income



Income Statement

Consolidated








(DKK'000)

YTD

YTD

Q2

Q2

Year



2015

2014

2015

2014

2014








Revenue

9,576

24,412

5,292

12,206

123,395

Production costs

(5,798)

-

(1,657)

-

(3,247)








Gross profit

3,778

24,412

3,635

12,206

120,148








Sales and marketing costs

(19,457)

(13,653)

(9,637)

(13,653)

(41,278)

Research and development costs

(39,127)

(51,044)

(18,363)

(24,420)

(90,111)

Administrative expenses

(27,573)

(17,732)

(11,549)

(9,983)

(47,363)








Operating result

(82,379)

(58,017)

(35,914)

(35,850)

(58,604)








Financial income

13,437

5,949

-

2,758

21,098

Financial expenses

(110)

(4,044)

(4,673)

(1,530)

(195)








Result before tax

(69,052)

(56,112)

(40,587)

(34,622)

(37,701)








Tax for the period

2,958

2,989

1,478

1,495

1,382








Net result for the period

(66,094)

(53,123)

(39,109)

(33,127)

(36,319)






















Basic and diluted EPS

(0.04)

(0.03)

(0.02)

(0.02)

(0.02)








Weighted average number of shares

1,663,085,535

1,661,684,858

1,663,167,653

1,662,527,283

1,662,266,639






















Statements of comprehensive income

Consolidated








(DKK'000)

YTD

YTD

Q2

Q2

Year



2015

2014

2015

2014

2014








Net result for the period

(66,094)

(53,123)

(39,109)

(33,127)

(36,319)

  Other comprehensive income:






  Items that may be subsequently reclassified






  to profit or loss:






  Currency translation differences, net of tax

(248)

75

11

49

(208)








  Other comprehensive income for the period

(248)

75

11

49

(208)








Total comprehensive income for the period

(66,342)

(53,048)

(39,098)

(33,078)

(36,527)

 

 


Balance sheet














Assets


Consolidated









(DKK'000)


30 June


30 June


31 Dec.




2015


2014


2014









Patent rights and software


1,090


441


1,134









Intangible assets


1,090


441


1,134









Property, plant and equipment


3,929


3,098


4,247









Property, plant and equipment


3,929


3,098


4,247









Non-current assets


5,019


3,539


5,381









Inventories


10,467


2,224


4,764









Trade receivables


1,895


-


25

Tax receivables


9,375


-


6,250

Other receivables


5,288


5,765


2,677

Prepayments


1,069


725


4,192









Receivables


17,627


6,490


13,144









Cash


191,064


264,240


270,434









Cash and cash equivalents


191,064


264,240


270,434









Current assets


219,158


272,954


288,342









Assets


224,177


276,493


293,723

 

 


Balance sheet














Equity & Liabilities


Consolidated









(DKK'000)


30 June


30 June


31 Dec.




2015


2014


2014









Share capital


166,334


166,252


166,300

Special reserve


407,289


407,289


407,289

Translation reserves


1,512


2,043


1,760

Retained earnings/loss


(381,609)


(343,935)


(322,101)









Equity


193,526


231,649


253,248









Trade payables


6,886


17,738


17,875

Tax payables


678


-


470

Deferred revenue


-


12,206


-

Other payables


23,087


14,900


22,130









Current liabilities


30,651


44,844


40,475









Liabilities


30,651


44,844


40,475









Equity and liabilities


224,177


276,493


293,723

 

 


Cash flow statements




Cash Flow Statement

Consolidated








(DKK'000)

YTD

YTD

Q2

Q2

Year



2015

2014

2015

2014

2014








Operating result

(82,379)

(58,017)

(35,914)

(35,850)

(58,604)








Share-based payment

6,500

4,971

3,822

3,188

9,744

Depreciation and amortization

714

405

360

203

993

Changes in working capital

(18,423)

(14,699)

(5,384)

(1,334)

(26,194)








Cash flow from operating activities before interest

(93,588)

(67,340)

(37,116)

(33,793)

(74,061)








Interest received

-

214

-

214

350

Interest paid

(110)

-

(89)

-

(195)

Corporate tax received

-

-

-

-

1,250

Corporate tax paid

-

-

-

2

(4,587)








Cash flow from operating activities

(93,698)

(67,126)

(37,205)

(33,577)

(77,243)















Purchase of property, plant and equipment

(272)

(117)

(272)

169

(2,547)








Cash flow from investing activities

(272)

(117)

(272)

169

(2,547)















Proceeds from issuance of shares, net

120

684

88

-

989








Cash flow from financing activities

120

684

88

-

989















Increase/(decrease) in cash

(93,850)

(66,559)

(37,389)

(33,408)

(78,801)

Cash at beginning of period

270,434

328,652

233,568

296,237

328,652

Exchange gains/(losses) on cash

14,480

2,147

(5,115)

1,411

20,583








Cash at end of period

191,064

264,240

191,064

264,240

270,434

 

 

Statement of changes in equity















Consolidated Equity










Number of
Shares


Share
Capital

Special
Reserves

Translation
Reserves

Retained
Earnings

Total





DKK'000

DKK'000

DKK'000

DKK'000

DKK'000










Equity as of 1 Jan. 2014

1,660,572,426


166,057

407,289

1,968

(296,272)

279,042










Net result for the period






(53,123)

(53,123)

Other comprehensive income for the period




75


75

Total comprehensive income





75

(53,123)

(53,048)










Warrant exercises

1,954,857


195



489

684

Share-based payment






4,971

4,971










Equity as of 30 June 2014

1,662,527,283


166,252

407,289

2,043

(343,935)

231,649










Net result for the period






16,804

16,804

Other comprehensive income for the period




(283)


(283)

Total comprehensive income





(283)

16,804

16,521










Warrant exercises

470,031


48



257

305

Share-based payment






4,773

4,773










Equity as of 31 Dec. 2014

1,662,997,314


166,300

407,289

1,760

(322,101)

253,248










Net result for the period






(66,094)

(66,094)

Other comprehensive income for the period




(248)


(248)

Total comprehensive income





(248)

(66,094)

(66,342)










Warrant exercises

343,416


34



86

120

Share-based payment






6,500

6,500










Equity as of 30 June 2015

1,663,340,730


166,334

407,289

1,512

(381,609)

193,526

Notes

1.         Accounting policies
The interim report is prepared in compliance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and in accordance with the NASDAQ OMX Copenhagen's financial reporting requirements for listed companies.

There have been no changes in accounting policies used for the interim report compared to the accounting policies used in the preparation of Veloxis Pharmaceuticals' annual report for 2014.

2.         Research and development costs
We track research and development costs by activity, as follows: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical programs. Research and development costs include personnel, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities, medical affairs and other costs including cost of premises, depreciation and amortization related to research and development activities. Research and development costs are charged to operations as incurred.

SOURCE Veloxis Pharmaceuticals



RELATED LINKS

http://www.veloxis.com
http://www.veloxis.com